|
LINKS
| |
CLASSIFICAZIONE
DEI LINFOMI B
Caratteristiche
immunofenotipiche e genotipiche delle forme incluse nella classificazione W.H.O.1999
_______________________________
LINFOMI
B
|
Precursor
B-lymphoblastic leukemia/lymphoma: |
|
slg-,
cytoplasmic µ chain 30%, CD19+, CD20-/+, CD22+, CD79a+, TdT+, HLA-DR+,
CD10+/-, CD34+/-, CD13-/+, CD33-/+, IgH gene rearrangement +/-, IgL gene
rearrangement -/+, TCR gene rearrangement -/+, variable cytogenetic
abnormalities |
B-cell
chronic lymphocytic leukemia (B-CLL)/small
lymphocytic lymphoma: (B-CLL) |
|
Faint
SIgM+, SIgD+/-, CIg-/+, panB+, CD5+, CD10-, CD23+, CD43+, CD11c-/+,
CD25-/+ (B-PLL) More likely strong SIg+, CD22+, and CD5-. All of above -
IgH and IgL gene rearrangements; trisomy 12-/+; 13q abnormalities-/+ |
|
Lymphoplasmacytic
lymphoma: |
|
SIgM+,
SIgD-/+, CIg+, PanB+, CD5-, CD10-, CD43+/-, CD25-/+; IgH and IgL gene
rearrangements |
| Mantle cell
lymphoma: |
| SIgM+, SIgD+,
lambda>kappa, PanB+, CD5+, CD10-/+, CD23-, CD43+, CD11c-, CD25-; IgH
and IgL gene rearrangements, t(11;14); bcl-1 gene rearrangements
(CCND1/cyclinD1/PRAD1) common |
Follicular
center lymphoma, follicular:
|
| SIg+ (usually IgM
+/- IgD, IgG, IgA), PanB+, CD10+/-, CD5-, CD23-/+, CD43-, CD11c-, CD25-;
overexpression of bcl-2 protein useful in distinction to reactive
follicles; IgH and IgL gene rearrangements, t(14;18) with rearranged bcl-2
gene in 70-95% of cases |
| Extranodal
marginal zone B-cell lymphoma (low-grade B-cell lymphoma of MALT type): |
| SIg+ (IgM or IgA or IgG),
SIgD-, CIg-/+, PanB+, CD5-, CD10-, CD23-, CD43-/+; IgH and IgL gene
rearrangements, bcl-1 and bcl-2 germline, trisomy 3 or t(11;18)(q21;q21)
may be seen |
| Nodal marginal
zone B-cell lymphoma: |
| SIgM+, SIgD-, CIg-/+,
PanB+, CD5-, CD10-, CD23-, CD43-/+; IgH and IgL gene rearrangements, bcl-1
and bcl-2 germline |
| Hairy cell
leukemia: |
| SIg+ (IgM, IgD,
IgG, or IgA), PanB+, DBA44+, CD11c++, CD25+, CD103+ (mucosal lymphocyte
antigen as detected by B-ly7), tartrate-resistant acid phosphatase+; IgH
and IgL gene rearrangements |
| Plasmacytoma/myeloma: |
| CIg+ (IgG, IgA,
rare IgD, IgM, or IgE or light chain only), PanB-, (CD19, CD20, CD22),
CD79a+/-, CD45-/+, HLA-DR-/+, CD38+, CD56+/-, EMA-/+, CD43+/-; IgH and IgL
gene rearrangements or deletions, occasional cases t(11;14) |
| Diffuse large
B-cell lymphoma: |
| SIg+/-, CIg-/+, PanB+,
CD45+/-, CD5-/+, CD10-/+ (weak); IgH and IgL gene rearrangements; bcl-2
gene rearranged in 30% of cases, bcl-6/LAZ3 gene (chromosome 3q27)
rearranged in 30% of cases, c-myc gene rearrangement uncommon |
| Primary
mediastinal large B-cell lymphoma: |
| SIg-/+, PanB+, (especially
CD20, CD79a), CD45+/-, CD15-, CD30-/+ (weak); IgH and IgL gene
rearrangements |
| Burkitt’s
lymphoma: |
| SIgM+,
PanB+, CD5-, CD10++, CD23-; IgH and IgL gene rearrangements, t(8;14) and
variants t(2;8) and t(8;22); rearranged c-myc gene. EBV common (95%) in
endemic cases and infrequent (15-20%) in sporadic cases, intermediate
incidence (30-40%) in HIV-positive cases |
|
